How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
18
IDNA Quote, Financials, Valuation and Earnings
Last price:
$22.97
Seasonality move
:
-10.49%
Day range:
$22.61 - $22.88
52-week range:
$21.53 - $25.80
Dividend yield:
0.98%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
12.9K
Avg. volume:
39.9K
1-year change:
0.26%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IHI
iShares US Medical Devices ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$22.83 | -- | -- | -- | $0.11 | 0.98% | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
$105.59 | -- | -- | -- | $0.09 | 0.41% | -- |
|
HQL
abrdn Life Sciences Investors
|
$13.60 | -- | -- | -- | $0.50 | 0% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$29.22 | -- | -- | -- | $0.00 | 0% | -- |
|
IBB
iShares Biotechnology ETF
|
$133.95 | -- | -- | -- | $0.06 | 0.29% | -- |
|
IHI
iShares US Medical Devices ETF
|
$59.30 | -- | -- | -- | $0.11 | 0.46% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 1.497 | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | 1.296 | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | 1.173 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.788 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 1.446 | -- | -- |
|
IHI
iShares US Medical Devices ETF
|
-- | 1.148 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IHI
iShares US Medical Devices ETF
|
-- | -- | -- | -- | -- | -- |
iShares Genomics Immunology and Healthcare ETF vs. Competitors
-
Which has Higher Returns IDNA or FXH?
First Trust Health Care AlphaDEX Fund has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat First Trust Health Care AlphaDEX Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- -
What do Analysts Say About IDNA or FXH?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Health Care AlphaDEX Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than First Trust Health Care AlphaDEX Fund, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than First Trust Health Care AlphaDEX Fund.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 FXHFirst Trust Health Care AlphaDEX Fund0 0 0 -
Is IDNA or FXH More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 0.981, which suggesting that the stock is 1.86% less volatile than S&P 500. In comparison First Trust Health Care AlphaDEX Fund has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.906%.
-
Which is a Better Dividend Stock IDNA or FXH?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.98%. First Trust Health Care AlphaDEX Fund offers a yield of 0.41% to investors and pays a quarterly dividend of $0.09 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. First Trust Health Care AlphaDEX Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or FXH?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than First Trust Health Care AlphaDEX Fund quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than First Trust Health Care AlphaDEX Fund's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while First Trust Health Care AlphaDEX Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for First Trust Health Care AlphaDEX Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- --
-
Which has Higher Returns IDNA or HQL?
abrdn Life Sciences Investors has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat abrdn Life Sciences Investors's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- HQLabrdn Life Sciences Investors-- -- -- -
What do Analysts Say About IDNA or HQL?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand abrdn Life Sciences Investors has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than abrdn Life Sciences Investors, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than abrdn Life Sciences Investors.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 HQLabrdn Life Sciences Investors0 0 0 -
Is IDNA or HQL More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 0.981, which suggesting that the stock is 1.86% less volatile than S&P 500. In comparison abrdn Life Sciences Investors has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.182%.
-
Which is a Better Dividend Stock IDNA or HQL?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.98%. abrdn Life Sciences Investors offers a yield of 0% to investors and pays a quarterly dividend of $0.50 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. abrdn Life Sciences Investors pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or HQL?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than abrdn Life Sciences Investors quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than abrdn Life Sciences Investors's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while abrdn Life Sciences Investors's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for abrdn Life Sciences Investors. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- HQLabrdn Life Sciences Investors-- -- -- --
-
Which has Higher Returns IDNA or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About IDNA or HTEC?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is IDNA or HTEC More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 0.981, which suggesting that the stock is 1.86% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.070, suggesting its more volatile than the S&P 500 by 6.985%.
-
Which is a Better Dividend Stock IDNA or HTEC?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.98%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or HTEC?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns IDNA or IBB?
iShares Biotechnology ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About IDNA or IBB?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than iShares Biotechnology ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is IDNA or IBB More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 0.981, which suggesting that the stock is 1.86% less volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.046%.
-
Which is a Better Dividend Stock IDNA or IBB?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.98%. iShares Biotechnology ETF offers a yield of 0.29% to investors and pays a quarterly dividend of $0.06 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or IBB?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
-
Which has Higher Returns IDNA or IHI?
iShares US Medical Devices ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat iShares US Medical Devices ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- IHIiShares US Medical Devices ETF-- -- -- -
What do Analysts Say About IDNA or IHI?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Medical Devices ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than iShares US Medical Devices ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than iShares US Medical Devices ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 IHIiShares US Medical Devices ETF0 0 0 -
Is IDNA or IHI More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 0.981, which suggesting that the stock is 1.86% less volatile than S&P 500. In comparison iShares US Medical Devices ETF has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.601%.
-
Which is a Better Dividend Stock IDNA or IHI?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 0.98%. iShares US Medical Devices ETF offers a yield of 0.46% to investors and pays a quarterly dividend of $0.11 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. iShares US Medical Devices ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or IHI?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than iShares US Medical Devices ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than iShares US Medical Devices ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while iShares US Medical Devices ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for iShares US Medical Devices ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- IHIiShares US Medical Devices ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
